Good positive Wilson’s update after this morning’s announcement. Maintains Overweight rating & 91c per share risked PT.
Note the final line of their analysis: “...this ability to double pembrolizumab responder rates is strategically attractive to pharma partners” and instead of saying “wtf is wrong with you investors” they instead say (again) that key positives are “perhaps underappreciated by the market”. Indeed!
Ann: Publication of Abstracts for ASCO 2023 Annual Meeting, page-23
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.3¢ |
Change
0.003(0.81%) |
Mkt cap ! $454.5M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 30.5¢ | $92.52K | 297.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 135217 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 94545 | 14 |
View Market Depth
| Last trade - 11.00am 04/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |